Synergy Rx Pharmacy Issues Recall Due to Lack of Sterility
The company has voluntarily recalled all lots of of human chorionic gonadotropin because of a lack of sterility assurance.
On Feb. 14, 2017, Synergy Rx Pharmacy announced a voluntary recall of all lots of of human chorionic gonadotropin (HCG) 5000 units/vial and 11,000 units/vial, distributed between June 1, 2016 and Dec. 22, 2016, because of a lack of sterility assurance. The recalled lots, which were packaged in 15 mL serum glass vials, were distributed to physician offices and clinics in Arizona, California, Wisconsin, and Minnesota.
As of Feb. 14, the company had not received any reports of adverse events due to the recalled product but it warns that use a product intended to be sterile that is not sterile could result in serious infections. The company is advising customers to stop use of the product and return any unused lots. Adverse events can be reported to FDA at www.fda.gov/medwatch/report.htm.
Source: FDA
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
